MarketCapExport financials
Avid Bioservices (CDMO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Avid Bioservices Balance Sheet 2024-2009 | CDMO
Brief overview of Avid Bioservices's balance sheet structure
The review uses the five latest available annual reports between 2020 and 2024.
Assets advanced +212.7% to $336.6 million from $107.6 million; annual growth near 33% reflects a fast increase in scale.
Liability growth of +319.4% exceeded asset growth of +212.7%, increasing reliance on outside funding.
The equity ratio is 18.1%, compared with 38.9% before. Low autonomy increases reliance on liabilities.
Net debt is $17.5 million, or 0.29x of equity. This is a conservative debt position.
The cash share moved from 33.7% to 11.3%. A higher figure generally provides more room in an adverse scenario.
The accumulated result is -$571.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
Avid Bioservices has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Avid Bioservices
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
17.5 M | 12 M | -79.6 M | -71.6 M | -9.41 M | -32.3 M | -42.3 M | -46.8 M | -61.4 M | -68 M | -77.5 M | -35.2 M | -18 M | -21.8 M | - | - |
Long Term Debt |
54.2 M | 49.1 M | 43.5 M | 96.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.35 M | 1.36 M | 3.11 M | 1.36 M | 1.23 M | - | - | - | - | - | - | - | - | 1.32 M | - | - |
Total Non Current Liabilities |
- | - | - | - | 21.2 M | 2.16 M | 2.16 M | 1.6 M | 1.4 M | 1.1 M | 639 K | 737 K | 1.14 M | 1.67 M | - | - |
Total Current Liabilities |
70.6 M | 215 M | 223 M | 70.9 M | 44.5 M | 23.2 M | 37.9 M | 62.9 M | 57.6 M | 37.3 M | 22.2 M | 20.6 M | 17.6 M | 17.7 M | - | - |
Total Liabilities |
276 M | 262 M | 261 M | 188 M | 65.7 M | 25.3 M | 40 M | 64.5 M | 59 M | 38.4 M | 22.8 M | 21.3 M | 18.8 M | 19.3 M | - | - |
Deferred Revenue |
39.9 M | 37.4 M | 48.4 M | 50.8 M | 29.1 M | 14.7 M | 10.9 M | 28.5 M | 10 M | 6.63 M | 5.24 M | 4.17 M | 3.65 M | 5.62 M | - | - |
Retained Earnings |
-572 M | -431 M | -431 M | -560 M | -571 M | -561 M | -559 M | -537 M | -509 M | -454 M | -403 M | -368 M | -338 M | -296 M | - | - |
Total Assets |
337 M | 452 M | 443 M | 266 M | 108 M | 78.4 M | 95.8 M | 118 M | 109 M | 97.5 M | 90.5 M | 45.1 M | 28.3 M | 34.8 M | - | - |
Cash and Cash Equivalents |
38.1 M | 38.5 M | 126 M | 170 M | 36.3 M | 32.4 M | 42.3 M | 46.8 M | 61.4 M | 68 M | 77.5 M | 35.2 M | 18 M | 23.1 M | 19.7 M | 10 M |
Book Value |
60.9 M | 189 M | 182 M | 77.7 M | 41.9 M | 53.1 M | 55.7 M | 53.6 M | 50.1 M | 59 M | 67.7 M | 23.8 M | 9.48 M | 15.4 M | - | - |
Total Shareholders Equity |
60.9 M | 189 M | 175 M | 77.7 M | 41.9 M | 53.1 M | 55.7 M | 53.6 M | 50.1 M | 59 M | 67.7 M | 23.8 M | 9.48 M | 15.4 M | 13.4 M | 901 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Avid Bioservices
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
52.9 M | 53.6 M | 54.9 M | 55.5 M | 48.6 M | 54.9 M | 40.9 M | 48.6 M | 42.7 M | 44 M | 44 M | 41.8 M | 2.09 M | 20.2 M | 20.2 M | 20.6 M | 23.8 M | 21.6 M | 21.6 M | 22.4 M | 23.5 M | - | 22.4 M | 23.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
279 M | 276 M | 275 M | 272 M | 253 M | 275 M | 265 M | 252 M | 272 M | 258 M | 258 M | 261 M | 255 M | 82.8 M | 82.8 M | 64.2 M | 59 M | 58.1 M | 58.1 M | 59 M | 65.7 M | - | 25.3 M | - | 25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
51.7 M | 37.7 M | 52.9 M | 46.4 M | 33 M | 52.9 M | 37.8 M | 33 M | 52.8 M | 59 M | 59 M | 48.4 M | 53.8 M | 47.7 M | 47.7 M | 31.4 M | 46.3 M | 26.4 M | 26.4 M | 22.2 M | 18.1 M | 14.6 M | 14.6 M | 17.3 M | 18 M | 6.63 M | 6.63 M | 7.47 M | 13.4 M | 26.4 M | 26.4 M | 18 M | 21.5 M | 15.4 M | 15.4 M | 9.69 M | 8.29 M | 5.75 M | 5.75 M | 3.61 M | 4.67 M | 4.33 M | 4.33 M | 3.47 M | 4.16 M | 5.06 M | 5.06 M | 6.22 M | 6.06 M | 2.55 M | 2.55 M | 2.01 M | 4.14 M | - | 2.01 M | 4.14 M | 5.62 M |
Retained Earnings |
-595 M | -577 M | -449 M | -443 M | -433 M | -449 M | -431 M | -433 M | -430 M | -547 M | -547 M | -431 M | -431 M | -562 M | -562 M | -564 M | -553 M | -566 M | -566 M | -564 M | -564 M | -561 M | -561 M | -560 M | -558 M | -562 M | -562 M | -551 M | -539 M | -532 M | -532 M | -524 M | -520 M | -497 M | -497 M | -481 M | -467 M | -441 M | -441 M | -428 M | -416 M | -393 M | -393 M | -383 M | -376 M | -359 M | -359 M | -355 M | -346 M | -327 M | -327 M | -316 M | -304 M | - | -316 M | -304 M | -296 M |
Total Assets |
323 M | 335 M | 455 M | 455 M | 443 M | 455 M | 450 M | 442 M | 451 M | 314 M | 314 M | 442 M | 430 M | 168 M | 168 M | 114 M | 271 M | 105 M | 105 M | 105 M | 102 M | 76.1 M | 76.1 M | 80.2 M | 84.7 M | 69.9 M | 69.9 M | 78.6 M | 100 M | 111 M | 111 M | 110 M | 106 M | 119 M | 119 M | 113 M | 92 M | 79.1 M | 79.1 M | 81.4 M | 87.6 M | 76.5 M | 76.5 M | 55.1 M | 53.3 M | 37.2 M | 37.2 M | 36.5 M | 31.5 M | 29.4 M | 29.4 M | 27.3 M | 27 M | - | 27.3 M | 27 M | 34.8 M |
Cash and Cash Equivalents |
33.4 M | 33.4 M | 30.7 M | 31.4 M | 24.9 M | 30.7 M | 59.9 M | 25.2 M | 115 M | 59.9 M | 150 M | 77.3 M | 126 M | 70.9 M | 70.9 M | 35.7 M | 160 M | 30.7 M | 30.7 M | 34 M | 28.9 M | 27.8 M | 27.8 M | 32.7 M | 37.5 M | 17.9 M | 17.9 M | 27.7 M | 37.3 M | 41.5 M | 41.5 M | 49.1 M | 44.2 M | 67.5 M | 67.5 M | 72 M | 59 M | 55.2 M | 55.2 M | 64.4 M | 73.3 M | 63.2 M | 63.2 M | 44.4 M | 41.6 M | 26.3 M | 26.3 M | 24.4 M | 19 M | 19.8 M | 19.8 M | 18.1 M | 16.5 M | 24.1 M | 18.1 M | 18.1 M | 16.5 M |
Book Value |
44.8 M | 58.6 M | 180 M | 183 M | 190 M | 180 M | 185 M | 191 M | 179 M | 56.6 M | 56.6 M | 181 M | 175 M | 85.4 M | 85.4 M | 49.4 M | 212 M | 47.1 M | 47.1 M | 46.2 M | 36.3 M | 76.1 M | 50.8 M | 80.2 M | 59.4 M | 69.9 M | 69.9 M | 78.6 M | 100 M | 111 M | 111 M | 110 M | 106 M | 119 M | 119 M | 113 M | 92 M | 79.1 M | 79.1 M | 81.4 M | 87.6 M | 76.5 M | 76.5 M | 55.1 M | 53.3 M | 37.2 M | 37.2 M | 36.5 M | 31.5 M | 29.4 M | 29.4 M | 27.3 M | 27 M | - | 27.3 M | 27 M | 34.8 M |
Total Shareholders Equity |
44.8 M | 58.6 M | 180 M | 183 M | 190 M | 180 M | 185 M | 190 M | 179 M | 185 M | 56.6 M | 181 M | 175 M | 85.4 M | 85.4 M | 49.4 M | 44.6 M | 47.1 M | 47.1 M | 49.2 M | 49.7 M | 53.1 M | 53.1 M | 54.8 M | 56.7 M | 31.5 M | 31.5 M | 42.9 M | 56 M | 40 M | 40 M | 42.2 M | 40.9 M | 59.9 M | 59.9 M | 69.2 M | 55.4 M | 49.8 M | 49.8 M | 58.8 M | 65.6 M | 55.1 M | 55.1 M | 35.6 M | 32.5 M | 17.4 M | 17.4 M | 12.7 M | 3.92 M | 12.9 M | 12.9 M | 12.5 M | 11.8 M | - | 12.5 M | 11.8 M | 15.4 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Avid Bioservices, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
